Literature DB >> 30137962

Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.

Kristin M Riching1, Sarah Mahan1, Cesear R Corona2, Mark McDougall2, James D Vasta1, Matthew B Robers1, Marjeta Urh1, Danette L Daniels1.   

Abstract

A new generation of heterobifunctional small molecules, termed proteolysis targeting chimeras (PROTACs), targets proteins for degradation through recruitment to E3 ligases and holds significant therapeutic potential. Despite numerous successful examples, PROTAC small molecule development remains laborious and unpredictable, involving testing compounds for end-point degradation activity at fixed times and concentrations without resolving or optimizing for the important biological steps required for the process. Given the complexity of the ubiquitin proteasomal pathway, technologies that enable real-time characterization of PROTAC efficacy and mechanism of action are critical for accelerating compound development, profiling, and improving guidance of chemical structure-activity relationship. Here, we present an innovative, modular live-cell platform utilizing endogenous tagging technologies and apply it to monitoring PROTAC-mediated degradation of the bromodomain and extra-terminal family members. We show comprehensive real-time degradation and recovery profiles for each target, precisely quantifying degradation rates, maximal levels of degradation ( Dmax), and time frame at Dmax. These degradation metrics show specific PROTAC and family member-dependent responses that are closely associated with the key cellular protein interactions required for the process. Kinetic studies show cellular ternary complex stability influences potency and degradation efficacy. Meanwhile, the level of ubiquitination is highly correlated to degradation rate, indicating ubiquitination stemming from productive ternary complex formation is the main driver of the degradation rate. The approaches applied here highlight the steps at which the choice of E3 ligase handle can elicit different outcomes and discern individual parameters required for degradation, ultimately enabling chemical design strategies and rank ordering of potential therapeutic compounds.

Mesh:

Substances:

Year:  2018        PMID: 30137962     DOI: 10.1021/acschembio.8b00692

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  56 in total

Review 1.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

2.  PROTAC Technology: Opportunities and Challenges.

Authors:  Hongying Gao; Xiuyun Sun; Yu Rao
Journal:  ACS Med Chem Lett       Date:  2020-03-12       Impact factor: 4.345

3.  A kinetic proofreading model for bispecific protein degraders.

Authors:  Derek W Bartlett; Adam M Gilbert
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-22       Impact factor: 2.745

4.  Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay.

Authors:  Caroline A Foley; Frances Potjewyd; Kelsey N Lamb; Lindsey I James; Stephen V Frye
Journal:  ACS Chem Biol       Date:  2019-12-27       Impact factor: 5.100

Review 5.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

6.  Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties.

Authors:  Saul Jaime-Figueroa; Alexandru D Buhimschi; Momar Toure; John Hines; Craig M Crews
Journal:  Bioorg Med Chem Lett       Date:  2019-12-13       Impact factor: 2.823

Review 7.  Emerging modes-of-action in drug discovery.

Authors:  Eric Valeur; Frank Narjes; Christian Ottmann; Alleyn T Plowright
Journal:  Medchemcomm       Date:  2019-06-25       Impact factor: 3.597

8.  The luminescent HiBiT peptide enables selective quantitation of G protein-coupled receptor ligand engagement and internalization in living cells.

Authors:  Michelle E Boursier; Sergiy Levin; Kris Zimmerman; Thomas Machleidt; Robin Hurst; Braeden L Butler; Christopher T Eggers; Thomas A Kirkland; Keith V Wood; Rachel Friedman Ohana
Journal:  J Biol Chem       Date:  2020-02-27       Impact factor: 5.157

9.  Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.

Authors:  Omer Gilan; Inmaculada Rioja; Rab K Prinjha; Mark A Dawson; Kathy Knezevic; Matthew J Bell; Miriam M Yeung; Nicola R Harker; Enid Y N Lam; Chun-Wa Chung; Paul Bamborough; Massimo Petretich; Marjeta Urh; Stephen J Atkinson; Anna K Bassil; Emma J Roberts; Dane Vassiliadis; Marian L Burr; Alex G S Preston; Christopher Wellaway; Thilo Werner; James R Gray; Anne-Marie Michon; Thomas Gobbetti; Vinod Kumar; Peter E Soden; Andrea Haynes; Johanna Vappiani; David F Tough; Simon Taylor; Sarah-Jane Dawson; Marcus Bantscheff; Matthew Lindon; Gerard Drewes; Emmanuel H Demont; Danette L Daniels; Paola Grandi
Journal:  Science       Date:  2020-03-19       Impact factor: 47.728

Review 10.  Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality.

Authors:  Milka Kostic; Lyn H Jones
Journal:  Trends Pharmacol Sci       Date:  2020-03-26       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.